Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME-1: Survival of Staphylococcus hominis A9 on Skin in Atopic Dermatitis
NCT05177328Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Staphylococcus hominis A9 in atopic dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Duration of ShA9 Survival on the Lesional Ventral Arm Skin at Day 24. Started Jul 2022; status: terminated.
02
Drugs
Staphylococcus hominis A9
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05177328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177328.